RT期刊文章SR电子T1与二丙酸倍氯米松治疗运动性哮喘儿童哮喘摩根富林明欧洲呼吸杂志乔和J FD欧洲呼吸学会SP 932欧元OP 937 10.1183 / 09031936.04.00141303 VO 24是6 A1 r·彼得森A1 l . Agertoft A1皮德森年2004 UL //www.qdcxjkg.com/content/188bet官网地址24/6/932.abstract AB新hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP)气溶胶显著增加药物输送到航空公司。因此,即使是低剂量的HFA-BDP应该有效,和目前的研究评估。一个随机、双盲、交叉研究是用来比较安慰剂的效果,HFA-BDPµg 50或100µg q.d。(QVARTM AutohalerTM;美国3 m医药、圣保罗、锰)运动诱发支气管狭窄和呼出一氧化氮(eNO)。14日试车后,25名儿童(为5 - 14岁)进入三四周治疗时期,隔开1周惨败。每一段时间后,在一秒钟用力呼气量(FEV1),一个练习测试后,eNO测量。显著的治疗效果没有遗留或时期影响被认为对eNO和最大运动后FEV1下降。安慰剂之间还是有差异的(FEV1下降= 27.9%;eNO = 14.4 ppb(含量),要么HFA-BDP剂量,但不是两个活动之间的剂量(FEV1下降50µg: = 20.8%, eNO =十亿分之9.3;FEV1下降100µg: = 20.9%, eNO =十亿分之8.9)。 In conclusion, low q.d. doses of hydrofluoroalkane-beclomethasone dipropionate reduced exhaled nitric oxide and exercise-induced bronchoconstriction. Further studies are needed to assess whether q.d. administration of beclomethasone dipropionate is as effective as b.i.d. administration. This study was supported by 3M Pharmaceuticals, St. Paul, MN, USA.